139 related articles for article (PubMed ID: 37625803)
21. Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans.
Chen YT; Chen WT; Huang WT; Wu CC; Chai CY
Kaohsiung J Med Sci; 2012 Oct; 28(10):545-9. PubMed ID: 23089320
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatofibrosarcoma protuberans and common fibrous histiocytoma (dermatofibroma).
Weinrach DM; Wang KL; Wiley EL; Laskin WB
Arch Pathol Lab Med; 2004 Oct; 128(10):1136-41. PubMed ID: 15387709
[TBL] [Abstract][Full Text] [Related]
23. Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans.
Schechter SA; Bresler SC; Patel RM
J Cutan Pathol; 2020 Oct; 47(10):913-916. PubMed ID: 32412128
[TBL] [Abstract][Full Text] [Related]
24. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
25. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
26. ETS-related Gene (ERG) is Differentially Expressed in Dermatofibroma (Fibrous Histiocytoma) as Compared With Dermatofibrosarcoma Protuberans and Hypertrophic Scars: A Pilot Immunohistochemical Study.
Hengy M; Veenstra J; Perry K; Ozog DM; Friedman BJ
Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):453-458. PubMed ID: 35510745
[TBL] [Abstract][Full Text] [Related]
27. Comparison of p53 expression in dermatofibrosarcoma protuberans and dermatofibroma: lack of correlation with proliferation rate.
Díaz-Cascajo C; Bastida-Iñarrea J; Borrego L; Carretero-Hernández G
J Cutan Pathol; 1995 Aug; 22(4):304-9. PubMed ID: 7499569
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of ERG immunostaining in dermatofibroma.
Yamada Y; Ichiki T; Susuki Y; Yamada-Nozaki Y; Tateishi Y; Furue M; Oda Y
J Clin Pathol; 2023 Aug; 76(8):536-540. PubMed ID: 35318257
[TBL] [Abstract][Full Text] [Related]
29. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
30. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
31. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Abenoza P; Lillemoe T
Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
[TBL] [Abstract][Full Text] [Related]
32. Phenotype and proliferation characteristics of cultured spindle-shaped cells obtained from normal human skin and lesions of dermatofibroma, Kaposi's sarcoma, and dermatofibrosarcoma protuberans: a comparison with fibroblast and endothelial cells of the dermis.
Bonish BK; Foreman KE; Gutierrez-Steil C; Nickoloff BJ
J Dermatol Sci; 1997 Nov; 16(1):52-8. PubMed ID: 9438908
[TBL] [Abstract][Full Text] [Related]
33. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.
Maekawa T; Jinnin M; Ohtsuki M; Ihn H
Eur J Dermatol; 2011; 21(4):534-8. PubMed ID: 21697041
[TBL] [Abstract][Full Text] [Related]
34. Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma.
Wang L; Xiang YN; Zhang YH; Tu YT; Chen HX
Br J Dermatol; 2011 Jan; 164(1):135-40. PubMed ID: 20849518
[TBL] [Abstract][Full Text] [Related]
35. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
Labonte S; Hanna W; Bandarchi-Chamkhaleh B
J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
[TBL] [Abstract][Full Text] [Related]
36. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
[TBL] [Abstract][Full Text] [Related]
37. Giant cell fibroblastoma in a child misdiagnosed as a dermatofibroma.
Nguyen CM; Burch JM; Fitzpatrick JE; Peterson SL; Weston WL
Pediatr Dermatol; 2002; 19(1):28-32. PubMed ID: 11860566
[TBL] [Abstract][Full Text] [Related]
38. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
39. Connexin 43 in Dermatofibroma and Dermatofibrosarcoma Protuberans: Diagnostic, Pathogenic, and Therapeutic Implications.
Fernandez-Flores A; Varela-Vazquez A; Mayan MD; Fonseca E
Am J Dermatopathol; 2023 Dec; 45(12):812-815. PubMed ID: 37982464
[TBL] [Abstract][Full Text] [Related]
40. The involvement of fibroblast growth factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma protuberans.
Ishigami T; Hida Y; Matsudate Y; Murao K; Kubo Y
J Med Invest; 2013; 60(1-2):106-13. PubMed ID: 23614918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
